ReproCELL Inc.

As of March 31, 2026, ReproCELL Inc. carries a market capitalization of 16.73B, placing it among publicly traded companies globally. Its enterprise value stands at 10.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ReproCELL Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, ReproCELL Inc. has 95.03M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, ReproCELL Inc. maintains a current ratio of 10.91, meaning it holds 10.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, ReproCELL Inc.'s stock has declined approximately 35.29% over the past 52 weeks. The 50-day moving average sits at 139.22, while the 200-day moving average is 150.00.

These figures are as of March 31, 2026. Total book value stands at 8.31B, with working capital of 6.72B providing operational flexibility.

ReproCELL Inc.'s most recent stock split took place on August 28, 2013 with a 1:5 split ratio.